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Abstract
Purpose Classical type of lobular neoplasia (LN) spans a spectrum of disease, including atypical lobular hyperplasia (ALH) 
and lobular carcinoma in situ (LCIS), classical lobular neoplasia (LN), and the three-tiered classification of lobular intraepi-
thelial neoplasia (LIN-1, -2, -3). This study addressed inter-observer variability of classical lobular neoplasias (LN) (B3 
lesions) in preoperative breast biopsies among breast and gynecopathologists
Methods A retrospective, observational, cross-sectional study was conducted. 40 preoperative digital images of breast core/
vacuum biopsies were analyzed by eight experienced breast- and gynecopathologists. Evaluation criteria were ALH, LCIS, 
LN classic, LIN-1, LIN-2, LIN-3, focal B3 (one focus), extensive B3 (> one focus). Kappa-index and Chi-square tests were 
used for statistics. Digital scanned slides were provided to each participant. Agreement between the categories was defined 
as at least six of eight (cut-off 75%) concordant diagnoses.
Results The highest agreement between eight pathologists was reached using the category lobular neoplasia (LN, classical), 
26/40 (65%) cases were diagnosed as such. Agreements in other categories was low or poor: 12/40 (30%) (ALH), 9/40 (22%) 
(LCIS), 8/40 (20%) (LIN-1), 8/40 (20%) (focal B3), 3/40 (7.5%) (LIN-2), and 2/40 (5%) (extensive B3). Chi-square-test 
(classical LN versus the other nomenclatures) was significant (p = 0.001137).
Conclusion Our data suggest that among Swiss breast pathologists, the most reproducible diagnosis for B3 lobular lesions 
is the category of classical LN. These data further support lack of consistent data in retrospective studies using different 
terminologies. Validation of reproducible nomenclature is warranted in further studies. This information is useful especially 
in view of retro- and prospective data analysis with different diagnostic categories.
Keywords Lobular neoplasia · Atypical lobular hyperplasia · Lobular carcinoma in situ · B3 lesion · Inter-observer 
variability
Introduction
Lobular neoplasia of the breast comprises a large variation 
in atypical epithelial proliferation within the acinar breast 
structures (Foote and Stewart 1941; Haagensen et al. 1978; 
King et al. 2015; King and Reis-Filho 2014; Lakhani et al. 
2016; Tavassoli 2003; WHO 2019; Wen and Brogi 2018). 
In low-grade lesions, several existing alternative terminolo-
gies such as classical lobular neoplasia (LN classical type) 
including both atypical lobular hyperplasia (ALH) and lobu-
lar carcinoma in situ (classical LCIS) and the so-called Lob-
ular Intraepithelial Neoplasia (LIN) covering LIN-1, LIN-2, 
LIN-3 (Lakhani et al. 2016; Tavassoli 2003; WHO 2019; 
Rageth et al. 2016, 2019) allow to classify the same lobular 
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breast lesion with different diagnostic terms. Although clini-
cal management of these alternative low-grade terminolo-
gies is quite similar and all are considered as risk factors 
and non-obligate precursor for breast cancer, there is still no 
single pathological factor to predict upgrade, progression, 
and/or local recurrence (Foote and Stewart 1941; Haagensen 
et al. 1978; King et al. 2015; King and Reis-Filho 2014; 
Lakhani et al. 2016; Tavassoli 2003; WHO 2019; Wen and 
Brogi 2018; Rageth et al. 2016, 2019; AGO 2019). On the 
contrary, high-grade lobular in situ lesions such as pleo-
morphic or florid LCIS/LN exhibit a biologically similar 
behavior and require the same management as their ductal 
carcinoma in situ (DCIS) counterpart (WHO 2019; Wen and 
Brogi 2018; AGO 2019; Shamir et al. 2019).
Inter-observer agreement data on different terminologies 
are sparse and these data point to improved agreement when 
favoring one category to more than one descriptive subgroup 
(AGO 2019; Choi et al. 2008; Fitzgibbons 2000; Gomes 
et al. 2014; Singh et al. 2018). In our study, we addressed 
the question on inter-observer agreement on six existing 
non-pleomorphic LN terminologies using 40 diagnostic LN 
breast core and vacuum biopsy cases with eight participating 
pathologists specialized in breast pathology.
Materials and methods
40 cases of breast core- and vacuum biopsies with the diag-
nosis B3 lesion and lobular neoplasia were retrieved from 
the Institute of Pathology and Molecular Pathology, Univer-
sity Hospital Zurich Switzerland, in the years 2012–2013. 
All cases were diagnostic cases from routine histological 
diagnostics. The diagnosis of lobular neoplasia and B3 cat-
egory was made on conventional hematoxylin–eosin (H&E) 
stains and confirmed with immunohistochemistry (E-Cad-
herin loss and/or catenin p120 cytoplasmic staining) in all 
cases at the time of the routine diagnostics.
The study was conducted within the project approved by 
the cantonal committee of the Canton Zurich (KEK-2012-
554). Informed consent was not necessary as all cases were 
analyzed in a fully anonymized way.
Study design
All eight participants of the study were members of the 
Working Group of Breast and Gynecopathology of the Swiss 
Society of Pathology. For the study, a digital link contain-
ing H&E images of the biopsies as well as an excel data 
sheet were sent to all participants. Participants were asked 
to assess the H&E images and to enter any of the following 
further diagnostic subcategory which they think would fit 
to the index case.
These categories were named as follows: atypical lobular 
hyperplasia (ALH), lobular carcinoma in situ of classical 
type (LCIS classical type), lobular intraepithelial neoplasia 
I, II, III (LIN-I, LIN-II, LIN-III), lobular neoplasia of clas-
sical type (LN, classical type), focal or extensive classical 
LN (one or more than one focus of LN), and others (different 
from the mentioned category). A given case could be classi-
fied in multiple categories by the participant (Figs. 1 and 2).
An agreement in classification of a lesion was defined if 
a category was entered by at least six out of participating 
eight pathologists.
Fig. 1  Flowchart of different 
terminologies of lobular neo-
plasia and their designation in 
the B classification. LN lobular 
neoplasia, ALH atypical lobular 
hyperplasia, LCIS lobular 
carcinoma in situ, LIN lobular 
intraepithelial neoplasia
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Statistical analyses
Results were analyzed using the Chi-square statistics and 
Kappa Fleiss to compare agreed diagnostic categories.
Results
The highest agreement between eight pathologists was 
reached using the category lobular neoplasia (LN, classical), 
26/40 (65%) cases were diagnosed as such. Agreements in 
other categories was low or poor: 12/40 (30%) (ALH), 9/40 
(22%) (LCIS), 8/40 (20%) (LIN-1), 8/40 (20%) (focal B3), 
3/40 (7.5%) (LIN-2), and 2/40 (5%) (extensive B3). Chi-
square statistic was significant for the differences on agree-
ment between classical LN versus the other nomenclatures 
(p = 0.001137). Kappa Fleiss could not be applied due to 
multiple answers per case (Fig. 3).
Discussion
This is the first study to address reproducibility among exist-
ing established designations for classical B3 lobular lesions. 
In this study, we could show that different existing termino-
logical categories all describing classical type lobular neo-
plasia of the breast are unequally reproduced among expert 
breast pathologists. Among the known diagnostic catego-
ries such as atypical lobular hyperplasia, lobular carcinoma 
in situ of classical type, lobular intraepithelial neoplasia I, 
II, III, and lobular neoplasia of classical type, the diagnos-
tic agreement varies from 5–65%. The terminology ‘lobular 
Fig. 2  Illustration of different histological appearances of lobular neoplasia of classical type. H&E stain
Fig. 3  Distribution on agreed 
terminological categories on 40 
diagnostic cases with lobular 
neoplasia. The highest agree-
ment was reached at classical 
lobular neoplasia (p = 0.001137)
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neoplasia of classical type’ reached the highest agreement 
with 65% among breast pathologists.
The term lobular neoplasia encompasses a spectrum of 
histological lesions with differences in extent and the degree 
of nuclear atypia (Foote and Stewart 1941; Haagensen et al. 
1978; King et al. 2015; King and Reis-Filho 2014; Lakhani 
et al. 2016; Tavassoli 2003; WHO 2019; Wen and Brogi 
2018; Jorns et al. 2014). The original paper by Foote and 
Stewart from 1941 described and defined the morphologi-
cal criteria and differences between ALH and LCIS as both 
lesions exhibiting the same low-grade monotonous nuclear 
atypia but differing quantitatively in their acinar involve-
ment (Foote and Stewart 1941; King et al. 2015; King and 
Reis-Filho 2014; Wen and Brogi 2018; Jorns et al. 2014). 
Alternative terminologies such as classical lobular neoplasia 
(LN classical type) including both ALH and LCIS as well as 
the term Lobular Intraepithelial Neoplasia (LIN) covering 
LIN-1, LIN-2, LIN-3 as consecutive morphological catego-
ries represent a further approach to classify the same lobular 
breast lesions (Lakhani et al. 2016; Tavassoli 2003; WHO 
2019; Rageth et al. 2016; AGO 2019). These lesions are 
considered both as risk-factor and non-obligate precursor 
for breast cancer in terms of uncertain malignant potential 
also categorized as B3 lesions in some guidelines (Lakhani 
et al. 2016; Tavassoli 2003; WHO 2019; Wen and Brogi 
2018; Rageth et al. 2016, 2019). Long-term cumulative risk 
of classical LN for breast cancer is 1–2% per year, resulting 
in 8–10 × relative risk for LCIS and 4–5 × relative risk for 
ALH (King et al. 2015; King and Reis-Filho 2014; Lakhani 
et al. 2016; WHO 2019; Rageth et al. 2016).
Morphological variants with high nuclear grade, with the 
presence of necrosis or with extensive involvement of the 
multiple acini, are considered as separate entities and are 
designated as pleomorphic LCIS/LN, florid LCIS/LN, or 
LIN-3, and are also categorized as B5a category (non-inva-
sive pre-malignant lesion) (Lakhani et al. 2016; Tavassoli 
2003; WHO 2019; Rageth et al. 2016; 2019). Pleomorphic 
LCIS/LN, florid LCIS/LN, or LIN-3 can morphologically 
mimic solid type of DCIS, but represent molecularly distinct 
entities (WHO 2019; Wen and Brogi 2018; Shamir et al. 
2019). However, lobular lesions in the B5a category behave 
biologically similar as their DCIS counterpart, have higher 
risk for local recurrence and progression to invasive cancer, 
are more often Her2 positive, and therefore, their clinical 
management is very similar to DCIS (WHO 2019; Wen and 
Brogi 2018; Shamir et al. 2019).
On the contrary, classical lobular neoplasia forms are 
known to have a different biological behavior in terms of 
local recurrence and development of synchronous or sub-
sequent breast cancer than the high-grade variants (King 
et al. 2015; King and Reis-Filho 2014; Wen and Brogi 2018; 
Rageth et al. 2016, 2019; Schmidt et al. 2018). Upgrade rate 
to in situ or invasive cancer in open excision specimens has 
been conflictingly reported in the literature varying from 
0 to 25% in some papers up to 50% (Rageth et al. 2016, 
2019; Schmidt et al. 2018). No association with common 
clinical risk factors as positive family history or age can be 
linked to clinical behavior, and until now, no single histo-
pathological factor could predict upgrade or development 
of concurrent or subsequent breast cancer (King et al. 2015; 
Rageth et al. 2016, 2019). However, clinical management of 
classical lobular neoplasia has undergone relevant modifica-
tions during the last decade, including the identification of 
imaging target lesions as visible lesions and the histological 
association to mammographic calcifications into the man-
agement workflow (Rageth et al. 2016, 2019; AGO 2019). 
Current therapeutic guidelines recommend open excision 
for classical LN forms in breast core biopsies if there is a 
target lesion on imaging and in case of any inconsistency 
between imaging modalities and pathological assessment 
(Rageth et al. 2016, 2019; AGO 2019). In all other clas-
sical LN cases, a conservation approach with a high-risk 
senological follow-up is acceptable, especially in diagnoses 
made by breast vacuum biopsy and if the radiological target 
has been removed (Rageth et al. 2016, 2019; AGO 2019).
Although this therapeutic approach has been the stand-
ard for all classical LN forms, until now, guidelines do not 
consider different subgroups of classical lobular neoplasia as 
ALH vs LCIS or LIN-1 vs LIN-2 (Rageth et al. 2016, 2019; 
AGO 2019). Classical forms of B3 LN lesions are mainly 
subjected to a very similar therapeutic workflow (Rageth 
et al. 2016, 2019; AGO 2019). The AGO (2019) guidelines 
specifically do not recommend the distinction between 
LIN-1 and LIN-2, because prognostic differences have not 
adequately been documented and proven until now, even 
though absolute risk for breast cancer development differs 
between ALH and classical LCIS (AGO 2019).
Reproducibility issues concerning a wide spectrum of 
pre-malignant breast lesions, biomarkers, or degree of atypia 
have been the subject of several previous papers (Shamir 
et al. 2019; Choi et al. 2008; Fitzgibbons 2000; Gomes et al. 
2014; Allison et al. 2016; Carney et al. 2016; Elmore et al. 
2015, 2016a, b; O’Malley et al. 2006; Onega et al. 2017; 
Schuh et al. 2010; Sloane et al. 1998; Tan et al. 2005; Wells 
et al. 2000). The use of immunohistochemistry with aberrant 
E-Cadherin staining combined with morphological criteria 
led to an excellent agreement (86.9%) of correctly classi-
fying in situ or invasive lobular carcinomas and rule out 
morphological differential diagnoses of duct lesions such 
as solid-type DCIS or invasive ductal carcinomas (Choi 
et al. 2008). Gomes et al. (2014) reported differential inter-
observer variability among pre-malignant breast lesions 
including atypical ductal hyperplasia, columnar cell lesions, 
lobular neoplasia, and DCIS in a large series of second opin-
ions. In this paper, ALH and LCIS had both had a substantial 
inter-observer agreement after external review (Kappa 0.62 
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vs 0.66) (Gomes et al. 2014). Similar data were observed in 
a study by Fitzgibbons, where ALH and LCIS were inad-
equately classified when considered as separate entities (17% 
and 58% correct diagnoses); however, diagnostic accuracy 
improved to 74% when both lesions were categorized as one 
entity (Fitzgibbons 2000). Our results corroborate with these 
observations, single entities such as ALH, classical LCIS, 
or LIN-1 or LIN-2 did not result in satisfactory agreement 
(10–30% agreement), only using one category as classical 
lobular neoplasia including all B3 entities had an improved 
agreement (65%), which was also statistically significant. 
Singh et al. (2018) reported on a similar trend on improved 
reproducibility when pleomorphic and florid lobular carci-
noma in situ were grouped into one diagnostic category.
As was also suggested by Haagensen et al. (1978) more 
than 4 decades ago and also supported by the current study, 
insufficient reproducibility between slightly different histo-
logical entities can be improved using one category as clas-
sical LN.
Similar issues were addressed in DCIS in several previous 
studies (Onega et al. 2017; Schuh et al. 2010; Sloane et al. 
1998; Wells et al. 2000). Comparing three DCIS classifica-
tion systems, the van Nuys system resulted in the highest 
diagnostic agreement in the Sloane project and by Shuh 
et al. (Kappa 0.42 and 0.37), although the final histological 
grading of DCIS was better reproducible using the Holland 
classification in the other studies (Kappa 0.53) (Schuh et al. 
2010; Sloane et al. 1998; Wells et al. 2000). Applying a 
two-tiered grading system in DCIS (as low vs high grade) as 
opposed with reference diagnoses, high-grade DCIS proved 
to be more robust than low grade (83% vs 46% agreement 
with reference diagnoses) (Onega et al. 2017).
Reproducibility issues in atypical ductal breast lesions, 
such as columnar cell lesions, flat epithelial atypia (FEA), 
atypical ductal hyperplasia (ADH), or DCIS show a simi-
larly unequal trend (Allison et al. 2016; Carney et al. 2016; 
O’Malley et al. 2006; Tan et al. 2005). Agreement for FEA 
varies in the literature from poor (Kappa 0.27) to excel-
lent (Kappa 0.83) (O’Malley et al. 2006; Tan et al. 2005). 
Regarding ADH, solid or micropapillary pattern with bor-
derline cytological atypia was shown to be associated with 
lower agreement than those with cribriform pattern and 
clearly monotonous atypia (Allison et al. 2016).
Differences and agreements in pathologist’s opinions in a 
broader range of breast surgical specimens were documented 
in several earlier papers (Carney et al. 2016; Elmore et al. 
2015; 2016a; b). Under- and overestimation of atypia and 
consistency in overall agreement with diagnostic standards 
were found between non-academic and academic patholo-
gists (77.6% vs. 46%) (Carney et al. 2016). Elmore et al. 
reported misinterpretation in terms of atypia as highest after 
one single evaluation (52.2%) and the level of diagnostic 
concordance as highest in invasive carcinoma and lowest for 
DCIS and atypia (Elmore et al. 2015, 2016a, b).
In summary, our results show that existing different termi-
nologies on classical form of LN in general have a poor-to-
substantial agreement among expert breast pathologists on 
the same lesion, except when using a single category of clas-
sical lobular neoplasia. Regarding therapeutic approaches, 
until now, there is no difference in management between 
ALH, LCIS, LIN-1, and LIN-2 or classical LN (Rageth 
et al. 2016, 2019; AGO 2019). Decisions for open surgery 
currently require discordant lesions between histology 
and imaging, a suspicious mass lesion in imaging or inad-
equately removed target lesions by vacuum-assisted biopsies 
(Rageth et al. 2016, 2019; AGO 2019). Although until now 
no single histopathological factor of classical LN diagnosis 
could be identified to predict upgrade or local recurrence, 
helpful morphological ancillary tools such as information 
on associated calcifications in LN and a rough LN extension 
in breast core and vacuum-assisted biopsies can contribute 
to management decisions and possibly enable image-based 
senological follow-up in larger subset of LN cases.
Funding No funding was necessary for this study.
Compliance with ethical standards 
Conflict of interest The authors has no conflict of interest and no com-
peting interest to declare.
Availability of data and material All data and material are available in 
request without any restriction.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
AGO (2019) AGO guidelines of the AGO breast committee 2019 
[Available from: https ://www.ago-onlin e.de/en/guide lines 
-mamma /march -2019/.
Allison KH, Rendi MH, Peacock S, Morgan T, Elmore JG, Weaver DL 
(2016) Histological features associated with diagnostic agreement 
in atypical ductal hyperplasia of the breast: illustrative cases from 
the B-Path study. Histopathology 69(6):1028–1046
1478 Journal of Cancer Research and Clinical Oncology (2020) 146:1473–1478
1 3
Carney PA, Allison KH, Oster NV, Frederick PD, Morgan TR, Gel-
ler BM et al (2016) Identifying and processing the gap between 
perceived and actual agreement in breast pathology interpretation. 
Mod Pathol 29(7):717–726
Choi YJ, Pinto MM, Hao L, Riba AK (2008) Interobserver variability 
and aberrant E-cadherin immunostaining of lobular neoplasia and 
infiltrating lobular carcinoma. Mod Pathol 21(10):1224–1237
Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Toste-
son AN et al (2015) Diagnostic concordance among pathologists 
interpreting breast biopsy specimens. JAMA 313(11):1122–1132
Elmore JG, Nelson HD, Pepe MS, Longton GM, Tosteson AN, Geller 
B et al (2016a) Variability in pathologists’ interpretations of indi-
vidual breast biopsy slides: a population perspective. Ann Intern 
Med 164(10):649–655
Elmore JG, Tosteson AN, Pepe MS, Longton GM, Nelson HD, Geller 
B et al (2016b) Evaluation of 12 strategies for obtaining second 
opinions to improve interpretation of breast histopathology: simu-
lation study. BMJ 353:i3069
Fitzgibbons PL (2000) Atypical lobular hyperplasia of the breast: 
a study of pathologists’ responses in the College of American 
pathologists performance improvement program in surgical 
pathology. Arch Pathol Lab Med 124(3):463–464
Foote FW, Stewart FW (1941) Lobular carcinoma in situ: a rare form 
of mammary cancer. Am J Pathol. 17(4):491–496
Gomes DS, Porto SS, Balabram D, Gobbi H (2014) Inter-observer 
variability between general pathologists and a specialist in breast 
pathology in the diagnosis of lobular neoplasia, columnar cell 
lesions, atypical ductal hyperplasia and ductal carcinoma in situ 
of the breast. Diagn Pathol 9:121
Haagensen CD, Lane N, Lattes R, Bodian C (1978) Lobular neopla-
sia (so-called lobular carcinoma in situ) of the breast. Cancer 
42(2):737–769
Jorns J, Sabel MS, Pang JC (2014) Lobular neoplasia: morphology and 
management. Arch Pathol Lab Med 138(10):1344–1349
King TA, Reis-Filho JS (2014) Lobular neoplasia. Surg Oncol Clin N 
Am 23(3):487–503
King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A et al 
(2015) Lobular carcinoma in situ: a 29-year longitudinal experi-
ence evaluating clinicopathologic features and breast cancer risk. 
J Clin Oncol 33(33):3945–3952
Lakhani SE, Schnitt SJ, Tan PH, van de Vivjer MJ (2016) WHO clas-
sification of tumors of the breast. IARC, Lyon
O’Malley FP, Mohsin SK, Badve S, Bose S, Collins LC, Ennis M et al 
(2006) Interobserver reproducibility in the diagnosis of flat epi-
thelial atypia of the breast. Mod Pathol 19(2):172–179
Onega T, Weaver DL, Frederick PD, Allison KH, Tosteson ANA, Car-
ney PA et al (2017) The diagnostic challenge of low-grade ductal 
carcinoma in situ. Eur J Cancer 80:39–47
Rageth CJ, Oflynn EA, Comstock C, Kurtz C, Kubik R, Madjar H 
et al (2016) First international consensus conference on lesions 
of uncertain malignant potential in the breast (B3 lesions). Breast 
Cancer Res Treat 159(2):203–213
Rageth CJ, Oflynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, 
Decker T et al (2019) Second international consensus confer-
ence on lesions of uncertain malignant potential in the breast (B3 
lesions). Breast Cancer Res Treat. 174(2):279–296
Schmidt H, Arditi B, Wooster M, Weltz C, Margolies L, Bleiweiss 
I et al (2018) Observation versus excision of lobular neoplasia 
on core needle biopsy of the breast. Breast Cancer Res Treat 
168(3):649–654
Schuh F, Biazus JV, Resetkova E, Benfica CZ, Edelweiss MI (2010) 
Reproducibility of three classification systems of ductal carci-
noma in situ of the breast using a web-based survey. Pathol Res 
Pract 206(10):705–711
Shamir ER, Chen YY, Chu T, Pekmezci M, Rabban JT, Krings G 
(2019) Pleomorphic and florid lobular carcinoma in situ variants 
of the breast: a clinicopathologic study of 85 cases with and with-
out invasive carcinoma from a single academic center. Am J Surg 
Pathol 43(3):399–408
Singh K, Paquette C, Kalife ET, Wang Y, Mangray S, Quddus MR et al 
(2018) Evaluating agreement, histological features, and relevance 
of separating pleomorphic and florid lobular carcinoma in situ 
subtypes. Hum Pathol 78:163–170
Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, 
Boecker W et al (1998) Consistency achieved by 23 European 
pathologists in categorizing ductal carcinoma in situ of the breast 
using five classifications. European Commission Working Group 
on Breast Screening Pathology. Hum Pathol. 29(10):1056–1062
Tan PH, Ho BC, Selvarajan S, Yap WM, Hanby A (2005) Pathological 
diagnosis of columnar cell lesions of the breast: are there issues 
of reproducibility? J Clin Pathol 58(7):705–709
Tavassoli FADP (2003) WHO classification of tumours, pathology and 
genetics of tumours of the breast and female genital organs. IARC 
Press, Lyon
Wells WA, Carney PA, Eliassen MS, Grove MR, Tosteson AN (2000) 
Pathologists’ agreement with experts and reproducibility of breast 
ductal carcinoma-in-situ classification schemes. Am J Surg Pathol 
24(5):651–659
Wen HY, Brogi E (2018) Lobular carcinoma in situ. Surg Pathol Clin 
11(1):123–145
WHO (2019) WHO classification of tumours, 5th edn, Vol. 2. Interna-
tional Agency for Research on Cancer (IARC), Lyon
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
